Readout for Arcus’ pancreatic cancer program could spur Gilead to exercise option

Early data showing clinical efficacy of a combination from Arcus in pancreatic cancer increases the likelihood that Gilead will exercise its option on the biotech’s potentially first-in-class molecule targeting CD73.

An interim readout from the Phase I/Ib ARC-8 trial showed that a combo including AB680 from Arcus Biosciences Inc. (NASDAQ:RCUS) led to an overall response rate of 41%, with seven partial responses among 17 evaluable patients with metastatic pancreatic ductal adenocarcinoma. One patient converted to a complete response after the Dec. 9, 2020, efficacy data cut-off...